R. Michael Carruthers

R. Michael Carruthers, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Edgewise Therapeutics, Inc., OnKure Therapeutics, Inc. and Alpine Immune Sciences, Inc. Between 2 December 2016 and 12 August 2025, the trades on record add up to 22 filings.

In open-market terms, that means 1 purchase worth €47k on one side and 9 sales worth €4.6M on the other. Netting one side against the other leaves €4.5M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants and 10 option exercises. 2025 to date brings no purchases and 2 sales.

The newest entry dates from 14 August 2025: an open-market sale of €16k, in Edgewise Therapeutics, Inc. The clock since the last published purchase (5 December 2016) now reads 3,626 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.